NEW YORK, April 29 (Reuters) - Gilead Sciences GILD.O has reached a $202 million settlement to resolve a civil fraud lawsuit accusing the company of paying kickbacks to doctors who agreed to prescribe its HIV drugs, the U.S. attorney's office in Manhattan said on Tuesday.
The settlement resolves claims that Gilead paid honoraria, meals and travel expenses to doctors who attended Gilead speaker events to induce them to prescribe several HIV drugs.
U.S. Attorney Jay Clayton said this violated the federal False Claims Act by causing claims to be paid by federal healthcare programs.
(Reporting by Jonathan Stempel in New York; Editing by Chris Reese)
((jon.stempel@thomsonreuters.com; +1 646 223 6317; Reuters Messaging: jon.stempel.thomsonreuters.com@reuters.net))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。